NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
3
0 (0%)
The current stock price of PLX is 3 USD. In the past month the price increased by 15.38%. In the past year, price increased by 163.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 207 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
PROTALIX BIOTHERAPEUTICS INC
2 University Plaza, Suite 100
Hackensack NEW JERSEY 07601 US
CEO: Dror Bashan
Employees: 213
Phone: 12016969345
The current stock price of PLX is 3 USD.
The exchange symbol of PROTALIX BIOTHERAPEUTICS INC is PLX and it is listed on the NYSE Arca exchange.
PLX stock is listed on the NYSE Arca exchange.
5 analysts have analysed PLX and the average price target is 14.79 USD. This implies a price increase of 393% is expected in the next year compared to the current price of 3. Check the PROTALIX BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PROTALIX BIOTHERAPEUTICS INC (PLX) has a market capitalization of 234.09M USD. This makes PLX a Micro Cap stock.
PROTALIX BIOTHERAPEUTICS INC (PLX) currently has 213 employees.
PROTALIX BIOTHERAPEUTICS INC (PLX) has a support level at 2.56. Check the full technical report for a detailed analysis of PLX support and resistance levels.
The Revenue of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to grow by 61.73% in the next year. Check the estimates tab for more information on the PLX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PLX does not pay a dividend.
PROTALIX BIOTHERAPEUTICS INC (PLX) will report earnings on 2025-05-09.
The PE ratio for PROTALIX BIOTHERAPEUTICS INC (PLX) is 100. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 3 USD. Check the full fundamental report for a full analysis of the valuation metrics for PLX.
The outstanding short interest for PROTALIX BIOTHERAPEUTICS INC (PLX) is 1.1% of its float. Check the ownership tab for more information on the PLX short interest.
ChartMill assigns a technical rating of 10 / 10 to PLX. When comparing the yearly performance of all stocks, PLX is one of the better performing stocks in the market, outperforming 98.3% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to PLX. PLX has only an average score on both its financial health and profitability.
Over the last trailing twelve months PLX reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -40% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.49% | ||
ROA | 3.99% | ||
ROE | 6.79% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to PLX. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 943.67% and a revenue growth 61.73% for PLX